View More

Participation in the 4th What's New in Robotics Surgery… Hip Surgery Robot Unveiled

• From Knee Replacement to Hip Replacement… Expansion of Orthopedic Surgical Robot Platform • Proven Precision and Safety Based on Over 30,000 Accumulated Surgeries Medical robotics company CUREXO (CEO Jaejun Lee) announced its participation in the 4th Robotic Joint Replacement Surgery Symposium, held on the 31st at Dragon City in Yongsan, Seoul.The symposium, hosted by the Korean Society for Computer Assisted Orthopaedic Surgery (CAOS Korea), consisted of five sessions and 19 lectures by leading experts in orthopedic surgery. It served as a platform to share trends and clinical experiences in robotic joint replacement surgery both domestically and internationally.CUREXO showcased its hip surgery robot, CUVIS-Joint THA, at the event, conducting demonstrations for medical professionals. Sanghoon Lee, Director of CUREXO's Technology Research Center, participated as a presenter in Session 1, where he introduced the company's flagship products, clinical data, and future technology development plans. Director Lee stated, "CUREXO has expanded the application of its robotic platform from knee replacement to now include hip replacement surgery." He emphasized that "CUVIS-Joint has demonstrated its precision and safety with more than 30,000 surgeries performed globally." The CUVIS-Joint THA robot analyzes 3D anatomical data in detail to a personalized surgical plan. During surgery, its real-time tracking and automatic correction features minimize deviations from the surgical plan, allowing for precise implantation of the artificial joint. Currently, CUVIS-Joint is actively being adopted and utilized not only in major general hospitals in Korea but also in medical institutions in India, Malaysia, Indonesia, and other countries.

View More

CUVIS Spine Successfully Performs First Spinal Surgery in Malaysia

• Successful Spinal Surgeries Performed with CUVIS Spine at KPJ Ipoh Specialist Hospital in Malaysia• Following the Joint Surgery Robot CUVIS Joint, Spinal Robot Now Supplied – Expanding Presence in the Malaysian MarketCUREXO, a medical robotics company, announced on the 27th that its spinal surgery robot, CUVIS Spine, was successfully utilized in two spinal surgeries at a local hospital in Malaysia. The surgeries were conducted at KPJ Ipoh Specialist Hospital located in the state of Perak, Malaysia. The hospital had previously adopted CUREXO's joint replacement robot, CUVIS Joint, and with the recent introduction of CUVIS Spine, the company has further solidified its presence within the hospital. CUREXO stated that the spinal surgeries were completed successfully, receiving positive evaluations in terms of both safety and precision. CUVIS Spine, developed with CUREXO's own technology, enables preoperative surgical planning and features a high-precision robotic arm and real-time navigation tools, allowing for faster, more convenient, and more accurate surgeries compared to conventional manual procedures.CUVIS Spine received regulatory approvals from Korea's MFDS in 2019, followed by Europe's CE and the U.S. FDA, and is currently being used in major hospitals both domestically and internationally. It has also been designated as an innovative medical technology and is undergoing evaluation at Severance Hospital and Pusan National University Yangsan Hospital for inclusion in the Korean national health insurance system. A CUREXO representative stated, "The successful application of CUVIS Spine in real surgeries at a Malaysian hospital is highly meaningful. Building on this case, we plan to accelerate the expansion of spinal surgery robots across the Southeast Asian market."

View More

JOA 2025

• CUVIS-Joint: Japanese PMDA-Approved Robotic Joint Surgery System Introduced• Expanding Collaboration with Japanese Medical Professionals at JOA 2024 in Tokyo (May 22–25) CUREXO Inc. (KOSDAQ: 060280), a medical robotics company, announced on May 22 that it is participating in the Japanese Orthopaedic Association (JOA) annual meeting being held in Tokyo from May 22 to 25. The JOA meeting is Japan's largest orthopedic academic event, bringing together experts in orthopedic research, treatment, and surgical outcomes, with over 20,000 members in attendance. At the event, CUREXO is showcasing its robotic joint surgery system CUVIS-Joint to local medical professionals through its Japanese partner, KYOCERA. In March, CUREXO received manufacturing and sales approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), paving the way for official market entry. The company also secured an exclusive sales agreement with the KYOCERA Group for the Japanese market.A CUREXO official stated, "Based on our partnership with KYOCERA, we aim to strengthen collaboration with hospitals and medical professionals in Japan and gradually expand our market share in the Japanese medical robotics industry."

View More

MDSAP Certification

•  Accelerating Global Expansion in the Medical Robotics Market by Enhancing Product Credibility and Regulatory EfficiencyCUREXO, a medical robotics company led by CEO Jae-Jun Lee, announced on the 21st that it has obtained MDSAP (Medical Device Single Audit Program) certification, which integrates regulatory audits for five major countries : the United States, Canada, Japan, Australia, and Brazil.MDSAP allows medical device manufacturers to undergo a single regulatory audit that satisfies the quality management requirements of all five participating countries. This certification significantly streamlines the approval process, as it can replace or reduce the need for individual audits in each country.With the MDSAP certification, CUREXO has not only strengthened the credibility of its product quality but also reduced the time and cost required for obtaining regulatory approvals in each target market. The certification is expected to serve as a critical turning point in the company's efforts to expand strategically into global markets.A CUREXO official stated, "We are continuously expanding regulatory approvals across key global markets. The MDSAP certification will not only support our entry into new export regions but also enhance trust among our international partners."

View More

Approval from Japan's PMDA

On March 17, CUREXO received approval from Japan's Pharmaceuticals and Medical Devices Agency(PMDA) for the manufacturing and sales of CUVIS-joint, a robotic system for artificial joint surgery. As a result, We will begin sales of the CUVIS-joint in Japan through KYOCERA Global, who holds the exclusive distribution rights in the country.

View More

AAOS 2025

• Unveil CUVIS-Joint THA for Hip Surgery at AAOS 2025• Operate Independent Booth at World's Largest Orthopedic Conference in San DiegoCUREXO Inc. (KOSDAQ: 060280), a leading medical robotics company, announced that it will operate its own booth at the American Academy of Orthopaedic Surgeons (AAOS) 2025 in San Diego. At this global event, CUREXO will introduce its newly developed CUVIS-Joint THA robotic system for total hip arthroplasty, alongside its established robotic systems for joint and spine surgeries—CUVIS-Joint and CUVIS-Spine. The CUVIS-Joint THA is specifically engineered to enhance the precision of implant placement in hip replacement surgeries. It offers customized simulation based on the individual patient's anatomy, beginning from the surgical planning stage. At AAOS 2025, Curexo plans to actively promote global expansion by conducting live product demonstrations and engaging in meetings with healthcare professionals and international distributors. Currently, CUREXO  exports its CUVIS-Joint, CUVIS-Spine, and Morning Walk rehabilitation robots primarily to India, and is expanding to markets including Russia, Taiwan, Pakistan, Indonesia, and Malaysia. CUREXO is also accelerating its entry into the North American and Japanese markets. A CUREXO official stated, "Through our participation in AAOS 2025, we aim to globally showcase our advanced medical robotics technology and expand our regulatory approvals and export destinations. We are committed to strengthening our international distributor network and increasing our global market share."

View More

CUREXO INC.'S ROBOTIC GAIT TRAINING SYSTEM, MORNING WALK S200, INSTALLED IN FIRST US INPATIENT REHABILITATION FACILITY

In continuing its strategic partnership with Curexo, Inc. announced last year, Harmonic Bionics has completed the first installation of Curexo's Morning Walk S200 at an inpatient rehabilitation facility in the US.The Morning Walk S200 is an FDA-registered robotic gait rehabilitation system with a virtual reality component that uses a saddle for weight support and individual foot plates to facilitate more natural walking patterns. Last year, the device was installed at the first outpatient facility in the country. St. David's Rehabilitation Hospital, which is located at St. David's Medical Center in Austin, TX, is the first inpatient rehabilitation facility in the US to offer gait training with Morning Walk for patients. St. David's Medical Center was recently named as the top performing Large Community Hospital in the U.S. on the annual Fortune/Merative 100 Top Hospitals® list. The hospital's 64-bed rehabilitation facility provides comprehensive inpatient and outpatient care for patients with neurological conditions, including stroke and orthopedic illnesses or injuries."This is a major milestone for the Morning Walk device as we continue to validate the technology in different settings allowing more patients to experience Morning Walk in America," said Harmonic Bionics CEO Christopher Prentice. "We are excited to see the device at such a renowned institution right here in Austin and look forward to working with the St. David's team."For more information on Morning Walk S200, please email info@morningwalk.us.About Harmonic Bionics, Inc.Harmonic Bionics aims to empower patients and their care providers by designing intelligent technology that facilitates data-driven treatment for neurological and musculoskeletal movement impairments. Our flagship product, Harmony SHR, is a bilateral upper extremity exoskeleton designed to provide unique value in three areas of practice: neuroscience and movement science research, movement disorder assessment, and rehabilitation. About Curexo, Inc.Curexo Inc. is dedicated to developing cutting edge medical robots with the aim to provide value in life beyond treatment for a healthier tomorrow. CUREXO manufactures two surgical robots, CUVIS-joint and CUVIS-spine, along with one rehabilitation robot, Morning Walk S200. Listed in the Korean Stock market, CUREXO plans to increase its scale by growing internationally and working with global partners. Find out more at www.curexo.com/english/ source : https://www.prnewswire.com/news-releases/curexo-incs-robotic-gait-training-system-morning-walk-s200-installed-in-first-us-inpatient-rehabilitation-facility-301783789.html?tc=eml_cleartime

View More

Bionik Laboratories' InMotion® Robotic Devices on Display at the Korea International Medical & Hospital Equipment Show (KIMES)

Bionik Laboratories Corp. (OTCPINK: BNKL), a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges, offering its technology to therapists directly and offering services to patients in its clinical centers, today announced its InMotion® Robots will be on display at the Korea International Medical & Hospital Equipment Show (KIMES) from March 23 ? March 26, 2023. Through the Company's exclusive distribution partner Curexo in South Korea, attendees looking for innovative medical technologies will be able to demo the devices live and learn more about their role in recovery following a stroke and other neurological conditions.Curexo, a recognized leader in medical device distribution and Bionik's distribution partner in South Korea, continues to penetrate the Asian market on behalf of Bionik. The Company received regulatory approval for the InMotion® robotics technology from the South Korean Ministry of Food and Drug Safety in early 2020. Curexo's recent sales and installations of the InMotion® devices in South Korea included Pusan National University's Yangsan Hospital (PNUYH), Seoul National University Hospital (SNUH), Myongji Choonhye Hospital, and various Veteran's hospitals.Bionik's fleet of InMotion® Robots for rehabilitation following a stroke help patients to regain arm and hand movement. Where conventional therapy alone can only allow patients to do 30-60 repetitive movements an hour, the InMotion® devices have patients completing 600 - 1,000 movements an hour. The robotic device assists patients as needed while it measures the position, speed and acceleration to adjust to the patient's needs during that session. In a recent whitepaper, Using Data Analytics to Quantify InMotion Robotic Systems' Impact on Neuroplasticity, improvement rates of patients utilizing InMotion® robotic devices measured upwards of 15-20% over a 14-day time-."We value our long-standing partnership with Curexo, and their commitment to bring advancements in stroke recovery care to the South Korea market," said Richard Russo Jr., CEO of Bionik Labs. "Our data-driven robotic therapy system has been featured in published research within dozens of medical journals, pointing to its effectiveness. We look forward to continuing to bring Bionik's proven therapeutic gains to Curexo's customers in the years ahead."Curexo will be showcasing Bionik's InMotion® devices at KIMES in their booth, located at 3F, Hall C, #C200. To learn more about KIMES 2023, please visit here: https://kimes.kr/eng/. To learn more about Bionik and its InMotion® devices, please visit here. https://bioniklabs.com/About Bionik Laboratories Corp.Bionik Laboratories is a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges. The Company offers its technology to therapists directly and offers services to patients in its clinical centers. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development. For more information, please visit www.Bioniklabs.com and connect with us on Twitter, LinkedIn, and Facebook.Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "possible," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology.Forward-looking statements may include, without limitation, statements regarding (i) the plans and ives of management for future operations, including plans or ives relating to the design, development and commercialization of robotic rehabilitation products and the roll-out of its recently-announced Neuro-Recovery Centers of Excellence strategy, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, including as a result of the acquisition and rebranding of the Company's Neuro-Recovery Centers of Excellence, and the future financial performance of any such Centers of Excellence the Company may acquire or launch (iv) the market and projected market for our existing and planned products and services and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above.Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, ives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward- looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing or increase revenue, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development and sales of our products and related insufficient cash flows and resulting illiquidity, the continued impact on the Company's business as a result of the Covid-19 pandemic, the Company's inability to expand the Company's business, including its recently launched Neuro-Recovery Centers of Excellence strategy, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.source : https://www.businesswire.com/news/home/20230323005413/en/Bionik-Laboratories%E2%80%99-InMotion%C2%AE-Robotic-Devices-on-Display-at-the-Korea-International-Medical-Hospital-Equipment-Show-KIMES

View More

THINK Surgical and CUREXO Announce Entry Into Development and Distribution Agreement

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced its entry into a development and distribution agreement with Curexo, Inc., a medical robotics specialist company based in South Korea. THINK and Curexo have a strong working relationship based on historical development collaboration and Curexo distributes THINK's TSolution One™ platform in Korea and Vietnam.Under the development and distribution agreement, THINK and Curexo will work together to include certain existing THINK technology and certain newly developed technology in Curexo's CUVIS-Joint orthopedic surgical robot platform. THINK will have exclusive rights to distribute the CUVIS-Joint robotic platform, including the additional technology, in the United States and other countries, including the United Kingdom and certain countries in the European Union.  The CUVIS-Joint robotic platform is currently being used by surgeons in Korea and India with great success. To date over 4,000 procedures have been performed. Curexo will continue to commercialize the CUVIS-Joint robotic platform, including new technology developed with THINK, outside of the countries in THINK's distribution territory. Curexo will also continue to distribute THINK's TSolution One™ platform in Korea and Vietnam.The CUVIS-Joint robotic platform is not yet cleared for sale in the United States. THINK will be responsible for seeking 510(k) clearance from the Food and Drug Administration (FDA) in the United States with support from Curexo to allow such sales. The companies will work together to seek regulatory clearance in other countries for the CUVIS-Joint robotic platform including additional technology."We are excited to deepen our relationship with Curexo and look forward to bringing the CUVIS-Joint platform to the United States and other markets," said Stuart Simpson, president and chief executive officer of THINK Surgical. "CUVIS-Joint is the next generation of active robot for joint replacement featuring an open implant library. As an open system that works with implants from multiple manufacturers, CUVIS-Joint is an outstanding fit within THINK's portfolio of products and services. THINK's open systems, including the CUVIS-Joint, offer a compelling alternative to closed systems which are limited to one manufacture's implants.""We are more than pleased to enter into this agreement with THINK, a long-standing financial and business collaborator of Curexo," said JJ Lee, chief executive officer of Curexo. "THINK is well positioned to successfully launch the CUVIS-Joint platform in these key markets, and Curexo has great confidence in the new leadership of THINK, led by CEO Stuart Simpson, given Stuart's deep experience in the orthopedic surgical robot business. We look forward to cooperating with THINK to obtain FDA clearance, develop new technology, and deliver new experiences with this next generation of active robot, thereby proving the value of the CUVIS-Joint platform to hospitals and surgeons in these important markets."About THINK Surgical®, Inc.THINK Surgical, Inc., a privately held U.S.-based medical device and technology company, develops, manufactures, and markets active robotics for orthopedic surgery. The TSolution One® Total Knee Application includes the only commercially available, active robot for total knee arthroplasty (TKA) utilizing an open implant library, supporting a variety of implant options.  The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide.THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent technology.  Please refer to the instructions for use for the TSolution One Total Knee Application for a complete list of indications, contraindications, warnings, and precautions. For additional product information, please visit www.thinksurgical.com.THINK Surgical and TSolution One are registered trademarks of THINK Surgical, Inc. ?2022 THINK Surgical, Inc. All rights reserved.About Curexo, Inc.Curexo Inc. is dedicated to developing cutting edge medical robots with the aim to provide value in life beyond treatment for a healthier tomorrow. Curexo manufactures two surgical robots, CUVIS-joint and CUVIS-spine, along with one rehabilitation robot, Morning Walk S200. Listed in the Korean Stock market, Curexo plans to increase its scale by growing internationally and working with global partners.Source : https://www.prnewswire.com/news-releases/think-surgical-and-curexo-announce-entry-into-development-and-distribution-agreement-301597044.html